Axis Securities has reiterated its BUY call on Kotak Mahindra Bank Limited, assigning a target price of Rs 515, implying an upside of 22% from current levels.

Indian Bank’s Q3FY26 performance underscores a phase of measured consolidation rather than aggressive expansion.

Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.

UltraTech Cement, India’s largest cement manufacturer, continues to outpace industry growth as capacity expansion, operational efficiencies, and infrastructure-led demand converge into a multi-year

Gujarat Themis Biosyn Limited (GTBL), a niche pharmaceutical manufacturer specializing in fermentation-based intermediates, is entering a decisive phase of strategic evolution. BP Equities Pvt.

Motilal Oswal Financial Services has reiterated a BUY call on Suzlon Energy, arguing that the recent correction in the stock has created a compelling risk-reward setup at a time when India’s renewa